Early Glycemic Control Assessment Based on Consensus CGM Metrics

Area of Science:

• Endocrinology
• Metabolic Diseases
• Biomedical Data Science

Background:

• Continuous glucose monitoring (CGM) has transformed diabetes management.
• Expert consensus defines clinical targets for CGM data interpretation using eight key metrics.
• A minimum of 14 days of CGM data is recommended for reliable assessment of glycemic control.

Purpose of the Study:

• To evaluate the accuracy of consensus CGM metrics derived from less than 14 days of data (intra-period analysis).
• To investigate the consistency of these metrics across two consecutive 14-day periods (inter-period analysis).

Main Methods:

• Analysis of real-world CGM data from 484 diabetes users (4726 periods) obtained via the Glooko app.
• Calculation and comparison of consensus CGM metrics using accumulated data up to 14 days versus full 14-day periods.
• Assessment of deviations for various metrics, including time in range (TIR) and time below range (TBR).

Main Results:

• Time in range (TIR) and average-based metrics showed low deviations with less than 14 days of data.
• Metrics for infrequent events, such as time below range (TBR), exhibited significant deviations with reduced data duration.
• Clear discrepancies were observed between consensus metrics calculated from two consecutive 14-day periods.

Conclusions:

• Interpreting CGM data with less than 14 days may be valuable in specific clinical scenarios.
• Treatment decisions based on critical metrics like TBR require at least 14 days of data due to substantial deviations with less data.
• Over-generalizing glycemic control conclusions across consecutive periods should be avoided due to observed inter-period discrepancies.